Abstract
The impact on adult disease, of prenatal programming and of the environment during infancy has been widely described. Yet the increased morbidity due to this prenatal and neonatal environment seems to occur ever more early. Indeed, recent studies detected the consequences of prenatal programming in childhood, making it also an immediate concern for paediatricians.
This review, focusing on oligonephropathy, aimed to give an up-dated view on when prenatal-programmed morbidity is first detectable, and on possible preventive strategies and treatments. As renal morbidity related to prenatal programming has been diagnosed in early childhood, at only two years old, it is now urgent to evaluate early strategies such as sports, low-protein or iron diets and antiproteinuric drugs, preventing an accentuation of glomerulosclerosis. A yearly follow-up seems appropriate for patients born small for gestation or preterm, including the measure of blood pressure and of albuminuria. A diet preventing protein and salt excess, and a smoking prohibition could delay the onset of glomerulosclerosis. The yearly follow-up would allow to diagnose it early enough to administer angiotensin converting enzyme inhibitors delaying the progression of renal sclerosis.Keywords: Oligonephropathy, low birth weight, hypertension
Current Pediatric Reviews
Title:Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond
Volume: 8 Issue: 4
Author(s): Rachel Vieux and Jean-Michel Hascoet
Affiliation:
Keywords: Oligonephropathy, low birth weight, hypertension
Abstract: The impact on adult disease, of prenatal programming and of the environment during infancy has been widely described. Yet the increased morbidity due to this prenatal and neonatal environment seems to occur ever more early. Indeed, recent studies detected the consequences of prenatal programming in childhood, making it also an immediate concern for paediatricians.
This review, focusing on oligonephropathy, aimed to give an up-dated view on when prenatal-programmed morbidity is first detectable, and on possible preventive strategies and treatments. As renal morbidity related to prenatal programming has been diagnosed in early childhood, at only two years old, it is now urgent to evaluate early strategies such as sports, low-protein or iron diets and antiproteinuric drugs, preventing an accentuation of glomerulosclerosis. A yearly follow-up seems appropriate for patients born small for gestation or preterm, including the measure of blood pressure and of albuminuria. A diet preventing protein and salt excess, and a smoking prohibition could delay the onset of glomerulosclerosis. The yearly follow-up would allow to diagnose it early enough to administer angiotensin converting enzyme inhibitors delaying the progression of renal sclerosis.Export Options
About this article
Cite this article as:
Vieux Rachel and Hascoet Jean-Michel, Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond, Current Pediatric Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/157339612803307714
DOI https://dx.doi.org/10.2174/157339612803307714 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Can We Move Forward After ADVANCE?
Vascular Disease Prevention (Discontinued) HPLC-DAD-Q-TOF/MS-Based Screening and Analysis of the Multiple Absorbed Bioactive Components in Rat Serum after Oral Administration of Xiexin Tang
Current Pharmaceutical Analysis Enhancing Cardiovascular Dynamics by Inhibition of Thrombospondin- 1/CD47 Signaling
Current Drug Targets Editorial Nutritional Therapy in Metabolic Syndrome
Current Vascular Pharmacology Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology Real-time Detection of Aortic Valve in Echocardiography using Convolutional Neural Networks
Current Medical Imaging Depression and its Relation with Uncontrolled Hypertension and Increased Cardiovascular Risk
Current Hypertension Reviews Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Epidemiology and Adverse Consequences of Hookah/Waterpipe Use: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in the Discovery and Development of Marine Natural Products with Cardiovascular Pharmacological Effects
Mini-Reviews in Medicinal Chemistry Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing
Current Pharmacogenomics and Personalized Medicine Diagnosis of Vulnerable Plaque and Vulnerable Patient by Coronary Angioscopy and Multi-detector Row Computed Tomography (MDCT) — From Invasive to Non-invasive Plaque Imaging
Vascular Disease Prevention (Discontinued) Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Exploring and Prioritization of Mobile-Based Self-Management Strategies for HIV Care
Infectious Disorders - Drug Targets